English
Arabic
French
-
Your Test Results
Check your Laboratory and Radiology results online here anytime, anywhere.Access now -
Find your Doctor
Choose the physician whose knowledge and training best suits your needsFind -
Covid-19 Information
MLH offers a variety of options for COVID-19 testing & vaccination. Find out the most recent information and gold standard guidelines.Go
Latest News
PALBOCICLIB REAL WORLD DATA IN ADVANCED AND METASTATIC BREAST CANCER TREATED: A MULTICENTER EXPERIENCE IN LEBANON
treated with palbociclib + ET in second and third lines (28.5% and 30.5%, respectively). Other pts received palbociclib in ≥4th lines. In 24,8% pts (26/105) palbociclib was combined with aromatase inhibitors, in other cases – with fulvestrant. Median follow-up time was 6.5 months (1.1–31.9), median progression free survival – 6.0 months (1.0–28.0). The median follow-upRead more
UMC Designation
A University Medical Hospital, Mount Lebanon Hospital It is with great pleasure and pride that we announce the designation of Mount Lebanon Hospital (MLH) as a University Medical Center as per the Ministry of Health’s decision nb 1/536, which officially places MLH among the list of University Hospitals in Lebanon. We value the collaboration withRead more
A non-klatskin tumor: A case report and review of intrabiliary hydatid cyst rupture
Mersad Alimoradi, Etienne El-Helou, Hassan Sabra, Pierre Hani, Raja Wakim Abstract Introduction A 64-year-old lady was diagnosed with having a klatskin type 3A tumor based on imaging, however, an alternative diagnosis was achieved during surgery. Case Presentation We present a case of a 64-year-old lady who presented for new-onset jaundice and was diagnosed with typeRead more
Latest Publications
PALBOCICLIB REAL WORLD DATA IN ADVANCED AND METASTATIC BREAST CANCER TREATED: A MULTICENTER EXPERIENCE IN LEBANON
treated with palbociclib + ET in second and third lines (28.5% and 30.5%, respectively). Other pts received palbociclib in ≥4th lines. In 24,8% pts (26/105) palbociclib was combined with aromatase inhibitors, in other cases – with fulvestrant. Median follow-up time was 6.5 months (1.1–31.9), median progression free survival – 6.0 months (1.0–28.0). The median follow-upRead moreRationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study
Jeroen Dauw, Malgorzata Lelonek, Isabel Zegri-Reiriz, Cynthia P Paredes-Paucar, Cornelia Zara, Varghese George, Marta Cobo-Marcos, Dorit Knappe, Dmitry Shchekochikhin, Annop Lekhakul, Milka Klincheva, Simone Frea, Òscar Miró, Diane Barker, Attila Borbély, Samer Nasr, Nawal Doghmi, Rafael de la Espriella, Jagdeep S Singh, Virginia Bovolo, Inês Fialho, Noel T Ross, Mieke van den Heuvel, Riad Benkouar,Read moreSurveillance of antimicrobial resistance in Lebanese hospitals: retrospective nationwide compiled data
Kamal Chamoun, Maya Farah, Georges Araj, Ziad Daoud, Rima Moghnieh, Pascale Salameh, Danielle Saade, Jacques Mokhbat, Emma Abboud, Monzer Hamze, Edmond Abboud, Tamima Jisr, Antoine Haddad, Rita Feghali, Nadim Azar, Mohammad El-Zaatari, Marwan Chedid, Christian Haddad, Mireille Zouain, Dib Nehme, Angelique Barakat, Rola Husni Abstract Antimicrobial resistance is closely linked to antimicrobial use and isRead more
MLH is JCI Accredited
Copyright © 2021- Mount Lebanon Hospital
